At CALYM, our vision is to pioneer transformative advancements in the understanding and treatment of lymphoid malignancies. We aspire to be a global leader in collaborative research, pushing the boundaries of knowledge to improve patient outcomes.
Our mission is to bring together the brightest minds from academia and the private sector to conduct innovative research in lymphoid malignancies. Through strategic partnerships, proactive research development, and catalytic initiatives, we aim to accelerate innovation and its transfer, secure funding, and drive positive change in the field.
By combining the expertise and resources of all its members, the Institut Carnot CALYM offers a unique R&D service in the diagnosis and treatment of lymphoma, from the identification of new targets to phase 3 international clinical trials and beyond.
Expertise, tools, models, platforms, databases and collections of biological resources can be rapidly mobilised to carry out your research programs.
Check out the latest news from Calym
And stay updated with all our news on LinkedIn!
Embark on a fascinating journey into the world of lymphomas, LLC, and related diseases with our exclusive “Calym’s RedTalks Webinars” series. Launched in the fall of 2020, these webinars are your passport to cutting-edge knowledge, expert insights, and the latest advancements in the field.
The consortium thrives on the dynamic synergy between preclinical and clinical research. The Think Tank Innovation, a cross-functional gathering of esteemed professionals, fosters innovative ideas and facilitates actionable projects in lymphoma research.
CALYM is a proactive organization that plays a pivotal role in advancing research in lymphoid malignancies by promoting collaboration, supporting academic research development, facilitating relationship-building, and catalyzing cross-disciplinary initiatives.
Explore our current collaborators and learn about the synergies driving our research forward.
Les instituts Carnot OPALE et CALYM et le Paris-Saclay Cancer Cluster s’associent pour accélérer la recherche en oncohématologie et soutenir l’innovation thérapeutique
Un partenariat inédit, lancé durant Septembre Rouge
Retrouvez le communiqué ici.
CALYM and Embleema’s combination of world-class capabilities brings unique R&D solutions to sponsors for enhanced patient recruitment, consent and engagement, fully-consented and auditable data interchange and generation of regulatory-grade evidence.
Embleema provides blockchain-enforced patient consent management for clinical and long-term follow-up studies and regulatory-grade evidence generation through its HIVE big data and bioinformatics platform currently in use by the U.S. Food and Drug Administration and by CDISC for defining evidence generation standards in cell and gene therapy. For more information, please visit this link.
Medical imaging data, including 2D histopathological sections and 3D PET-CT images, are crucial for the diagnosis and monitoring of patients with lymphoma. Although histopathology remains the cornerstone of lymphoma diagnosis, pathological data can be challenging to generate through automated procedures as they consist of images that require subjective interpretation by pathologists.
This hinders the reproducibility of pathological results, including lymphoma typing, and can significantly impact the management of lymphoma patients.
The collaboration between the Carnot CALYM Institute and Euranova aims to address these challenges by developing cutting-edge AI solutions to assist physicians in their therapeutic decisions.
With a commitment to fostering open innovation, the Institut Carnot Calym is proud to endorse the ATLAS project, an ambitious 4-year public/private collaboration, led by scientists Dr Sandrine Roulland, Dr Bertrand Nadel and Dr Pierre Milpied from the French National Institute Of Health And Medical Research (Inserm) through the Centre d’Immunologie de Marseille-Luminy and the Translation Medicine Team from Bristol Myers Squibb (BMS), and supported by Canceropole Provence-Alpes-Côte d’Azur.
Implementing cutting-edge techniques and state-of-the-art high-resolution and dynamic analysis of tumors within their microenvironment, the research teams are building a cell “ATLAS” to unveil the key biological parameters associated with transformation, tumor growth, relapse and resistance to treatment. This innovative and disruptive research project benefits from biological samples from the CeVi collection of live lymphoma cells set up by CALYM and the clinical expertise of LYSA members.
Empowered by this groundbreaking and exemplary partnership, researchers are transcending sector and disciplinary confines, working collaboratively to produce results with tangible diagnostic and theranostic implications that will, in the long run, directly benefit patients.
CALYM is an non-profit organization (Association Loi 1901) that accelerates innovation and its transfer to industry in the field of malignant lymphoid diseases. Working in partnership with academia and industry, it has a professional team dedicated to partnership research and academic investment. As manager of the Calym Carnot Institute, CALYM coordinates the expertise and skills of its members to support innovative and ambitious research projects that have a real impact on patients.
The Carnot Institutes OPALE and CALYM, together with the Paris-Saclay Cancer Cluster, join forces to accelerate research in onco-hematology and support therapeutic innovation.